Duchenne muscular dystrophy: CRISPR/Cas9 treatment

被引：41
|
作者：
Mendell, Jerry R. [1 ,2 ,3 ]
Rodino-Klapac, Louise R. [1 ,2 ,3 ]
机构：
[1] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA
[2] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH 43205 USA
[3] Ohio State Univ, Columbus, OH 43205 USA
来源：
CELL RESEARCH | 2016年 / 26卷 / 05期
关键词：
MOUSE MODEL; MUSCLE;
D O I：
10.1038/cr.2016.28
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
A novel approach to gene correction by genome editing shows great promise as a treatment for Duchenne muscular dystrophy (DMD). CRISPR/Cas9 delivered by adeno-associated virus to a mouse model for DMD demonstrated improvement in function and histology.
引用
收藏
页码：513 / 514
页数：2
相关论文
共 50 条
  • [1] Duchenne muscular dystrophy: CRISPR/Cas9 treatment
    Jerry R Mendell
    Louise R Rodino-Klapac
    Cell Research, 2016, 26 : 513 - 514
  • [2] Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy
    Lim, Kenji Rowel Q.
    Yoon, Chantal
    Yokota, Toshifumi
    JOURNAL OF PERSONALIZED MEDICINE, 2018, 8 (04):
  • [3] Role of CRISPR/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies
    Agrawal, Pooja
    Harish, Vancha
    Mohd, Sharfuddin
    Singh, Sachin Kumar
    Tewari, Devesh
    Tatiparthi, Ramanjireddy
    Vishwas, Sukriti
    Sutrapu, Srinivas
    Dua, Kamal
    Gulati, Monica
    LIFE SCIENCES, 2023, 330
  • [4] The Role of CRISPR/Cas9 in Revolutionizing Duchenne's Muscular Dystrophy Treatment: Opportunities and Obstacles
    Ali, Ahsan
    Rahman, Md Yakeen
    Sheikh, Danish
    GLOBAL MEDICAL GENETICS, 2024, 11 (04): : 349 - 357
  • [5] Development of Nanoparticles to Deliver a CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy
    Emami, Michael R.
    Young, Courtney S.
    Ji, Ying
    Pyle, April D.
    Meng, Huan
    Spencer, Melissa J.
    MOLECULAR THERAPY, 2018, 26 (05) : 284 - 285
  • [6] A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9
    Sui, Tingting
    Lau, Yeh Siang
    Liu, Di
    Liu, Tingjun
    Xu, Li
    Gao, Yandi
    Lai, Liangxue
    Li, Zhanjun
    Han, Renzhi
    DISEASE MODELS & MECHANISMS, 2018, 11 (06)
  • [7] Further development of a CRISPR/Cas9 platform for 60% of Duchenne muscular dystrophy patients
    Fernandez, Karla
    FASEB JOURNAL, 2017, 31
  • [8] Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy
    Mollanoori, Hasan
    Rahmati, Yazdan
    Hassani, Bita
    Mehr, Meysam Havasi
    Teimourian, Shahram
    GENES & DISEASES, 2021, 8 (02) : 146 - 156
  • [9] Spell-checking nature: interrogating the versatility of the CRISPR/Cas9 system for the treatment of Duchenne Muscular Dystrophy
    Wojtal, D.
    Kemaladewi, D. U.
    Malam, Z.
    Abdullah, S.
    Wong, T. W. Y.
    Hyatt, E.
    Pereira, S.
    Stavropoulos, J.
    Mouly, V.
    Mamchaoui, K.
    Muntoni, F.
    Voit, T.
    Gonorazky, H.
    Dowling, J. J.
    Mendoza-Londono, R.
    Ivakine, E.
    Cohn, R. D.
    HUMAN GENE THERAPY, 2015, 26 (10) : A15 - A15
  • [10] Spell Checking Nature: A Therapeutic Use of the CRISPR/Cas9 System in Duchenne Muscular Dystrophy
    Wojtal, Daria
    Kemaladewi, Dwi U.
    Malam, Zeenat
    Abdullah, Sarah
    Hyatt, Elzbieta
    Huang, Victoria
    Mouly, Vincent
    Voit, Thomas
    Muntoni, Francesco
    Ivakine, Evgueni A.
    Cohn, Ronald D.
    MOLECULAR THERAPY, 2015, 23 : S223 - S224
12345